I now have comprehensive textbook material across all levels. Here is the complete framework.
Prevention Framework for Tuberculosis (TB) - An Infectious Disease
TB is a model infectious disease for a prevention framework. Unlike T2DM (where the focus is primarily on lifestyle modification), TB prevention has a distinct infectious disease logic: break the chain of transmission at every possible point - from the environment, to the host, to the infected case.
Natural History of TB (Basis of the Framework)
Mycobacterium tuberculosis in the environment
↓
Exposure via airborne droplet nuclei from an infectious source
↓
Primary infection (90% contained by immune system)
↓
LATENT TB INFECTION (LTBI) ← asymptomatic, non-infectious, Mantoux +ve
↓ [10% lifetime reactivation risk; 5% in first 2 years]
↓ [Higher risk with HIV, malnutrition, DM, silicosis, immunosuppression]
Active Pulmonary TB (sputum smear +ve) ← INFECTIOUS - 10-15 secondary cases/year
↓
Progressive disease → cavitation, haemoptysis, respiratory failure
↓
Extra-pulmonary TB (miliary, meningitis, spine, abdomen)
↓
Disability (destroyed lung, Pott's disease, paralysis) → Death
Each stage is the target of a prevention level. Critically, one smear-positive untreated case infects an estimated 10-15 people per year - making the infectious case the engine of the epidemic.
LEVEL 0 - Primordial Prevention
Phase: Before any risk factors or social conditions favouring TB emerge
Goal: Prevent the social, environmental, and host conditions that make populations vulnerable to TB
TB is fundamentally a disease of poverty. Its determinants are social, not just microbiological.
| Intervention | Action |
|---|
| Poverty alleviation | Improve income, employment, and social equity - poor nutrition and overcrowding are the deepest drivers of TB burden |
| Improved housing | Reduce overcrowding; increase ventilation; reduce indoor air pollution - all reduce the density of infectious droplet nuclei |
| Nutritional improvement | Malnutrition impairs cell-mediated immunity, the primary defence against M. tuberculosis; ensure adequate protein, calories, and micronutrients |
| Tobacco and alcohol control | Smoking damages airways and impairs mucociliary clearance; alcohol causes immunosuppression - both increase TB risk |
| Reduce HIV prevalence | HIV is the most powerful risk factor for reactivation of LTBI; HIV control is primordial prevention for TB |
| Mass health education | Educate communities about TB transmission, symptoms, stigma reduction, and the importance of early presentation |
LEVEL 1 - Primary Prevention
Phase: Susceptible host in an environment where M. tuberculosis is present
Goal: Prevent TB infection (exposure prevention) and prevent disease in those exposed (host protection)
Primary prevention in TB has two components: environmental/source control and host protection via BCG vaccination and chemoprophylaxis.
A. Environmental and Source Reduction
| Measure | Detail |
|---|
| Ventilation | Adequate air exchange in homes, hospitals, clinics, prisons, and congregate settings dilutes infectious aerosol concentration |
| Natural light and UV exposure | UV radiation kills M. tuberculosis; sunlit, well-ventilated environments reduce transmission |
| Airborne infection control (AIC) | In healthcare settings: negative-pressure isolation rooms; N95 respirators for healthcare workers; UV germicidal irradiation |
| Infection control in high-risk settings | Prisons, homeless shelters, mining communities, hospitals - all require specific AIC guidelines |
| Pasteurization and boiling of milk | Controls bovine TB (M. bovis) transmitted via infected milk |
B. BCG Vaccination (Specific Protection)
BCG is the only vaccine against TB and one of the most widely administered vaccines in the world, given under India's Universal Immunization Programme.
| Feature | Detail |
|---|
| Vaccine | Live attenuated M. bovis (Bacille Calmette-Guérin); Danish 1331 strain (used in India) |
| Aim | Induce artificial primary infection → stimulate acquired resistance → reduce morbidity and mortality from primary TB in those most at risk |
| Route | Intradermal (ID), left deltoid region |
| Dose | 0.1 mg in 0.1 ml for children >4 weeks; 0.05 ml for newborns <4 weeks |
| Schedule | At birth (or as soon as possible after) - under UIP |
| Who benefits most | Children under 5 - BCG protects powerfully against severe disseminated forms (miliary TB, TB meningitis); less effective against adult pulmonary TB |
| Contraindications | Active TB, immunocompromised states (HIV with low CD4), high-dose steroids |
"The aim of BCG vaccination is to induce a benign, artificial primary infection which will stimulate an acquired resistance to possible subsequent infection with virulent tubercle bacilli, and thus reduce the morbidity and mortality from primary tuberculosis among those most at risk."
C. Chemoprophylaxis - Preventive Treatment of Latent TB (LTBI)
Not everyone with LTBI needs treatment - but high-risk groups do.
Priority target groups for LTBI treatment:
| High-risk Group | Reason |
|---|
| Children <5 years, household contacts of smear+ve case | Underdeveloped immunity; rapid progression to disease |
| PLHIV (People Living with HIV) | Most powerful reactivation risk factor - 20-30x higher |
| People with silicosis | Impaired lung clearance |
| People with diabetes mellitus | Impaired immune function; 3x higher TB risk |
| People with chronic renal failure | Immunosuppressed |
| Prisoners, homeless, illicit drug users | High transmission settings |
| Immigrants from high-burden to low-burden countries | |
| Recent close contacts of infectious cases | |
Recommended LTBI treatment regimens (WHO):
| Regimen | Duration |
|---|
| Isoniazid (INH) daily | 9 months (preferred) |
| INH + Rifapentine once weekly | 12 weeks |
| Rifampicin daily | 4 months (better tolerability than INH) |
| INH + Rifampicin daily | 3-4 months |
LEVEL 2 - Secondary Prevention
Phase: Active TB disease present - symptomatic or pre-symptomatic
Goal: Early case detection and prompt treatment to cure the patient AND interrupt transmission (protecting the community = primary prevention for contacts)
"Effective anti-microbial treatment reduces infectivity by 90 per cent within 48 hours."
This is the most powerful component of TB control:
"The most powerful weapon, however, is the combination of case-finding and treatment."
A. Case Detection (Finding the Submerged Iceberg)
1. Passive Case Finding
- Over 60% of pulmonary TB patients develop symptoms (persistent cough, fever, haemoptysis, night sweats, weight loss) and seek care on their own
- All chest symptomatics presenting at any health facility are tested for TB
- This is the main strategy in high-burden countries - maximally cost-effective
2. Intensified/Active Case Finding (ICF)
Provider-initiated, targeted at vulnerable groups who may not seek care:
| Strategy | How |
|---|
| Community screening | Door-to-door visits; mobile screening vans; targeted invitation of contacts |
| Institutional screening | Systematic active screening in hospitals, prisons, homeless shelters, mines |
| Contact tracing | All household and close contacts of smear-positive cases screened |
3. Case-Finding Tools
| Tool | Use |
|---|
| Sputum Smear Microscopy (ZN/fluorescent) | First-line; rapid; detects smear-positive cases |
| CBNAAT/NAAT (CB-NAAT, TrueNat) | Rapid molecular diagnosis; detects M.TB + rifampicin resistance in 2 hours; preferred for children, PLHIV, extrapulmonary TB |
| Culture (LJ medium / MGIT) | Gold standard; 2-8 weeks; used for drug-resistant TB follow-up |
| Line Probe Assay (LPA) | Detects drug resistance to RIF, INH (FL-LPA) and fluoroquinolones (SL-LPA) |
| Chest X-ray | Useful for smear-negative PTB, children, miliary TB; not routine for smear+ve |
| Tuberculin Skin Test (Mantoux) | Detects infection (LTBI); 1 TU PPD-RT 23 used in India |
| IGRA | Interferon-gamma release assay; detects LTBI; unaffected by BCG |
B. Treatment - DOTS (Directly Observed Treatment Short-course)
Adequate treatment cures TB and eliminates the patient as a source of infection.
DOTS Strategy - 5 Components (NTEP/RNTCP):
- Political will and administrative commitment - sustained government support
- Quality-assured sputum smear microscopy - diagnosis before treatment
- Adequate supply of quality-assured short-course chemotherapy drugs - free of cost
- Directly Observed Treatment (DOT) - a DOT provider watches every dose (ensures adherence, prevents resistance)
- Systematic monitoring and accountability - case registers, outcome tracking
Standard treatment regimens:
| Category | Regimen | Duration |
|---|
| New DS-TB cases | 2HRZE / 4HRE | 6 months (2 intensive + 4 continuation) |
| Previously treated | Based on DST | Per drug sensitivity result |
| MDR-TB | Bedaquiline + longer regimen | 18-24 months |
H = Isoniazid, R = Rifampicin, Z = Pyrazinamide, E = Ethambutol
Why DOTS works:
- Reduces infectivity within 48 hours of starting treatment
- Prevents emergence of drug resistance
- Achieves >85% cure rates
- Protects the community by eliminating the infectious source
C. Contact Investigation
Every identified case triggers investigation of household and close contacts:
- Screen all contacts for symptoms, Mantoux test, CBNAAT
- Children <5 and PLHIV contacts → offer preventive treatment (LTBI regimen)
- Identify secondary cases early before further spread
LEVEL 3 - Tertiary Prevention
Phase: Established TB with complications or disability
Goal: Limit disability; prevent sequelae; rehabilitate patients to productive life
A. Disability Limitation
| Complication | Intervention |
|---|
| Drug-resistant TB (MDR/XDR) | Regimens based on drug sensitivity testing; longer-course regimens; newer drugs (bedaquiline, delamanid) |
| TB meningitis | Corticosteroids + anti-TB therapy; reduces mortality and neurological sequelae |
| Pott's disease (spinal TB) | Bracing, spinal surgery for deformity/cord compression |
| Haemoptysis | Bronchoscopy, embolization; surgical resection if needed |
| Pleural/pericardial complications | Aspiration, drainage; pericardectomy for constrictive pericarditis |
| Miliary TB | Intensive anti-TB treatment with steroids |
| TB and HIV co-infection | Concurrent ART + anti-TB treatment; careful drug interaction management |
B. Rehabilitation
With effective chemotherapy, the proportion needing formal rehabilitation has greatly reduced. Groups still requiring it:
| Need | Intervention |
|---|
| Destroyed lung / respiratory disability | Pulmonary rehabilitation - graded exercise, breathing techniques, oxygen therapy |
| Post-surgical lung resection | Physical and vocational rehabilitation |
| Chronically ill, still sputum-positive | Sheltered accommodation; nutritional support; continued treatment supervision |
| Pott's disease with paralysis | Physiotherapy, orthotics, vocational retraining |
| Psychological impact | Counselling; TB support groups; addressing stigma |
| Nutritional rehabilitation | Supplementary nutrition programmes (Nikshay Poshan Yojana in India - ₹500/month) |
C. Surveillance and Programme Monitoring
"Surveillance is an integral part of any effective tuberculosis programme."
Two aspects:
- Epidemiological surveillance: annual infection rates (ARI); incidence and mortality trends - shows whether the TB problem is static, increasing or decreasing
- Programme surveillance: BCG coverage rates; treatment success rates; cure rates; default rates; drug resistance patterns
National Programme: NTEP (India)
The National Tuberculosis Elimination Programme (previously RNTCP), aligned with WHO's END TB Strategy (target: eliminate TB by 2025 in India):
- Vision: Zero deaths, disease, and suffering due to TB
- Built on 5-component DOTS, expanded under STOP TB and End TB frameworks
- Nikshay portal: Digital TB notification and patient tracking system
- Nikshay Poshan Yojana: Nutritional support ₹500/month for all TB patients
- Target: 80% reduction in TB incidence and 90% reduction in TB deaths by 2030 (vs 2015 baseline)
Complete Framework at a Glance
┌────────────────────────────────────────────────────────────────────────────┐
│ PREVENTION FRAMEWORK: TUBERCULOSIS │
├──────────────┬────────────────────┬──────────────────┬─────────────────────┤
│ LEVEL │ TARGET │ MODE │ KEY ACTIONS │
├──────────────┼────────────────────┼──────────────────┼─────────────────────┤
│ PRIMORDIAL │ Population - │ Social policy │ Poverty reduction, │
│ │ social conditions │ Education │ better housing, │
│ │ │ │ nutrition, HIV ctrl │
├──────────────┼────────────────────┼──────────────────┼─────────────────────┤
│ PRIMARY │ Susceptible host │ BCG vaccine │ BCG at birth (UIP) │
│ │ Environment │ Chemoprophylaxis │ INH/RIF for LTBI │
│ │ │ AIC measures │ Ventilation, UV, │
│ │ │ │ isolation rooms │
├──────────────┼────────────────────┼──────────────────┼─────────────────────┤
│ SECONDARY │ Active TB cases │ Case detection │ Sputum microscopy, │
│ │ Contacts │ DOTS treatment │ CBNAAT, ICF, DOTS │
│ │ │ Contact tracing │ 6-month regimen │
├──────────────┼────────────────────┼──────────────────┼─────────────────────┤
│ TERTIARY │ Complicated/ │ Disability limit.│ MDR-TB treatment, │
│ │ Disabled TB │ Rehabilitation │ surgery, physio, │
│ │ │ Surveillance │ nutrition support │
└──────────────┴────────────────────┴──────────────────┴─────────────────────┘
Key Difference: TB vs T2DM Prevention Frameworks
| Feature | TB (Infectious) | T2DM (Chronic NCD) |
|---|
| Main driver | Infectious agent (M. tuberculosis) | Lifestyle risk factors |
| Primordial focus | Social determinants (poverty, housing) | Lifestyle habits (diet, activity) |
| Primary prevention | BCG vaccine + source control + chemoprophylaxis | Lifestyle modification + Metformin |
| Secondary prevention | Case-finding + DOTS (curing cases = preventing new infections) | Screening + glycaemic control |
| Secondary benefit | Curing one patient prevents 10-15 new infections | Controlling one patient mainly benefits that individual |
| Tertiary | Rehabilitation; MDR-TB management | Diabetic clinic; complication management |
| Programme | NTEP (End TB) | NPCDCS |
Source: Park's Textbook of Preventive and Social Medicine, pp. 214-234 & 481-485